Opendata, web and dolomites

ALKATRAS SIGNED

ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ALKATRAS project word cloud

Explore the words cloud of the ALKATRAS project. It provides you a very rough idea of what is the project "ALKATRAS" about.

cosset    bio    plan    roche    calibre    nurture    pharma    environment    recognised    cohort    perform    individual    kinase    smes    science    internationally    mechanisms    coordinated    complemented    network    committee    personal    stage    connected    guided    efficacious    supervised    competitive    varionostics    sofigen    training    competence    skills    secondments    13    sciences    prevalent    competent    perspectives    phd    instigated    oncogenic    primary    laboratories    malignancies    train    sectors    biomedical    net    participation    erialcl    international    environments    interface    life    confident    lymphoma    local    galkem    cambridge    poses    transferable    15    balanced    multidisciplinary    exposed    human    integrating    therapies    excellent    mechanistic    anaplastic    tissuegnostics    fellows    conducts    etn    courses    recruited    career    prominent    eria    oncogene    fellow    panel    collaborative    alk    clinical    coordinate    broaden    thereby    independent    incorporated    scientists    forefront    functional    toxic    translational    generation    groups    academic   

Project "ALKATRAS" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://alkatras.erialcl.net
 Total cost 3˙849˙199 €
 EC max contribution 3˙849˙199 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2015
 Funding Scheme MSCA-ITN-ETN
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 546˙575.00
2    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 574˙216.00
3    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 525˙751.00
4    GOETEBORGS UNIVERSITET SE (GOETEBORG) participant 263˙659.00
5    UNIVERSITA DEGLI STUDI DI TORINO IT (TORINO) participant 258˙061.00
6    UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA IT (MILANO) participant 258˙061.00
7    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 249˙216.00
8    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 249˙216.00
9    JUSTUS-LIEBIG-UNIVERSITAET GIESSEN DE (GIESSEN) participant 249˙216.00
10    UNIVERSITAETSKLINIKUM FREIBURG DE (FREIBURG) participant 249˙216.00
11    Masarykova univerzita CZ (BRNO STRED) participant 232˙422.00
12    LUDWIG BOLTZMANN GESELLSCHAFT GMBH AT (WIEN) participant 193˙585.00
13    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) participant 0.00
14    BIOLUTION GMBH AT (WIEN) partner 0.00
15    Cambridge Life sciences UK (Cambridge) partner 0.00
16    Central European Society of Anti-Cancer Research (CESAR) AT (WIEN) partner 0.00
17    GALKEM SRL IT (Monza) partner 0.00
18    MEDIZINISCHE UNIVERSITAT GRAZ AT (GRAZ) partner 0.00
19    Roche Austria AT (Vienna) partner 0.00
20    Sofigen CZ (Brno) partner 0.00
21    The Naked Scientists UK (Cambridge) partner 0.00
22    TISSUEGNOSTICS GMBH AT (VIENNA) partner 0.00
23    VARIONOSTIC GMBH DE (ULM) partner 0.00

Map

 Project objective

This ETN is embedded into an established international research programme; The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA; www.erialcl.net) is an existing and functional network of 13 partners, which will cosset and nurture a cohort of early stage researchers to become confident, competent, independent and well-connected European scientists with excellent career perspectives. ERIA was instigated to coordinate research into ALK-related malignancies to facilitate the development of less-toxic and more efficacious therapies. ALK is increasingly recognised as a prevalent oncogene in a number of human malignancies and therefore poses a prominent clinical problem, which requires coordinated research into its oncogenic mechanisms. ERIA now conducts a collaborative multidisciplinary research programme at the interface of biomedical and bio-mechanistic approaches, which will be an excellent environment to train the next generation of European scientists. The 15 recruited fellows will be incorporated into international academic study groups (all partners of the ERIA network) to perform high calibre research and also will be exposed to environments from other sectors to broaden their experience. Secondments will include technical training within individual laboratories and SMEs (TissueGnostics, Galkem, Cambridge Life Sciences, Sofigen and Varionostics) as well as large Pharma (Roche). Training through research will be complemented with a balanced programme of transferable skills and access to local courses. The training of each fellow will be guided by a personal career development plan and supervised by a PhD committee panel. The primary goal of the network is to train the recruited fellows by participation in an internationally competitive research programme and integrating them into an international network. Thereby providing competence in state-of-the-art research and development at the forefront of translational science.

 Deliverables

List of deliverables.
ALCL transcriptome database Websites, patent fillings, videos etc. 2020-04-16 14:19:29
ALKATRAS website developed and updated Websites, patent fillings, videos etc. 2020-04-16 14:19:40
Therapy Synergism database Websites, patent fillings, videos etc. 2020-04-16 14:19:34

Take a look to the deliverables list in detail:  detailed list of ALKATRAS deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Geeta Sharma, Ines Mota, Luca Mologni, Enrico Patrucco, Carlo Gambacorti-Passerini, Roberto Chiarle
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
published pages: 62, ISSN: 2072-6694, DOI: 10.3390/cancers10030062
Cancers 10/3 2019-07-09
2018 Ricky Trigg, Suzanne Turner
ALK in Neuroblastoma: Biological and Therapeutic Implications
published pages: 113, ISSN: 2072-6694, DOI: 10.3390/cancers10040113
Cancers 10/4 2019-07-09
2018 Ines Garces de los Fayos Alonso, Huan-Chang Liang, Suzanne Turner, Sabine Lagger, Olaf Merkel, Lukas Kenner
The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas
published pages: 93, ISSN: 2072-6694, DOI: 10.3390/cancers10040093
Cancers 10/4 2019-07-09
2018 Cosimo Lobello, Vasilis Bikos, Andrea Janikova, Sarka Pospisilova
The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability
published pages: 64, ISSN: 2072-6694, DOI: 10.3390/cancers10030064
Cancers 10/3 2019-07-09
2018 Nina Prokoph, Hugo Larose, Megan Lim, G. Burke, Suzanne Turner
Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
published pages: 99, ISSN: 2072-6694, DOI: 10.3390/cancers10040099
Cancers 10/4 2019-07-09
2018 Ivonne Montes-Mojarro, Julia Steinhilber, Irina Bonzheim, Leticia Quintanilla-Martinez, Falko Fend
The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)
published pages: 107, ISSN: 2072-6694, DOI: 10.3390/cancers10040107
Cancers 10/4 2019-07-09
2018 Serena Stadler, Vijay Singh, Fabian Knörr, Christine Damm-Welk, Wilhelm Woessmann
Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
published pages: 114, ISSN: 2072-6694, DOI: 10.3390/cancers10040114
Cancers 10/4 2019-07-09
2016 Melanie R. Hassler, Walter Pulverer, Ranjani Lakshminarasimhan, Elisa Redl, Julia Hacker, Gavin D. Garland, Olaf Merkel, Ana-Iris Schiefer, Ingrid Simonitsch-Klupp, Lukas Kenner, Daniel J. Weisenberger, Andreas Weinhaeusel, Suzanne D. Turner, Gerda Egger
Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling
published pages: 596-608, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2016.09.018
Cell Reports 17/2 2019-09-04
2018 Nikolai Schleussner, Olaf Merkel, Mariantonia Costanza, Huan-Chang Liang, Franziska Hummel, Chiara Romagnani, Pawel Durek, Ioannis Anagnostopoulos, Michael Hummel, Korinna Jöhrens, Antonia Niedobitek, Patrick R. Griffin, Roberto Piva, Henrike L. Sczakiel, Wilhelm Woessmann, Christine Damm-Welk, Christian Hinze, Dagmar Stoiber, Bernd Gillissen, Suzanne D. Turner, Eva Kaergel, Linda von Hoff, Michael Grau, Georg Lenz, Bernd Dörken, Claus Scheidereit, Lukas Kenner, Martin Janz, Stephan Mathas
The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma
published pages: 1994-2007, ISSN: 0887-6924, DOI: 10.1038/s41375-018-0045-9
Leukemia 32/9 2019-07-09
2018 Rafael B. Blasco, Enrico Patrucco, Ines Mota, Wei-Tien Tai, Roberto Chiarle
Comment on “ALK is a therapeutic target for lethal sepsis”
published pages: eaar4321, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aar4321
Science Translational Medicine 10/471 2019-07-09
2019 Peng Liu, Liwei Zhao, Jonathan Pol, Sarah Levesque, Adriana Petrazzuolo, Christina Pfirschke, Camilla Engblom, Steffen Rickelt, Takahiro Yamazaki, Kristina Iribarren, Laura Senovilla, Lucillia Bezu, Erika Vacchelli, Valentina Sica, Andréa Melis, Tiffany Martin, Lin Xia, Heng Yang, Qingqing Li, Jinfeng Chen, Sylvère Durand, Fanny Aprahamian, Deborah Lefevre, Sophie Broutin, Angelo Paci, Amaury Bongers, Veronique Minard-Colin, Eric Tartour, Laurence Zitvogel, Lionel Apetoh, Yuting Ma, Mikael J. Pittet, Oliver Kepp, Guido Kroemer
Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer
published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-019-09838-y
Nature Communications 10/1 2019-07-09
2019 Barbara Maurer, Harini Nivarthi, Bettina Wingelhofer, Ha Thi Than Pham, Michaela Schlederer, Tobias Suske, Reinhard Grausenburger, Ana-Iris Schiefer, Michaela Prchal-Murphy, Doris Chen, Susanne Winkler, Olaf Merkel, Christoph Kornauth, Maximilian Hofbauer, Birgit Hochgatterer, Gregor Hoermann, Andrea Hoelbl-Kovacic, Jana Prochazkova, Cosimo Lobello, Abbarna A. Cumaraswamy, Johanna Latzka, Melitta Kitzwögerer, Andreas Chott, Andrea Janikova, Šárka Pospíšilova, Joanna I. Loizou, Stefan Kubicek, Peter Valent, Thomas Kolbe, Florian Grebien, Lukas Kenner, Patrick T. Gunning, Robert Kralovics, Marco Herling, Mathias Müller, Thomas Rülicke, Veronika Sexl, Richard Moriggl
High activation of STAT5A drives peripheral T-cell lymphoma and leukemia
published pages: haematol.2019.21, ISSN: 0390-6078, DOI: 10.3324/haematol.2019.216986
Haematologica 2019-07-09
2019 Matteo Menotti, Chiara Ambrogio, Taek-Chin Cheong, Chiara Pighi, Ines Mota, Seth H. Cassel, Mara Compagno, Qi Wang, Riccardo Dall’Olio, Valerio G. Minero, Teresa Poggio, Geeta Geeta Sharma, Enrico Patrucco, Cristina Mastini, Ramesh Choudhari, Achille Pich, Alberto Zamo, Roberto Piva, Silvia Giliani, Luca Mologni, Clayton K. Collings, Cigall Kadoch, Carlo Gambacorti-Passerini, Luigi D. Notarangelo, Ines M. Anton, Claudia Voena, Roberto Chiarle
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma
published pages: 130-140, ISSN: 1078-8956, DOI: 10.1038/s41591-018-0262-9
Nature Medicine 25/1 2019-07-09
2019 Peng Liu, Liwei Zhao, Jonathan Pol, Sarah Levesque, Adriana Petrazzuolo, Christina Pfirschke, Camilla Engblom, Steffen Rickelt, Takahiro Yamazaki, Kristina Iribarren, Laura Senovilla, Lucillia Bezu, Erika Vacchelli, Valentina Sica, Andréa Melis, Tiffany Martin, Lin Xia, Heng Yang, Qingqing Li, Jinfeng Chen, Sylvère Durand, Fanny Aprahamian, Deborah Lefevre, Sophie Broutin, Angelo Paci, Amaury Bongers, Veronique Minard-Colin, Eric Tartour, Laurence Zitvogel, Lionel Apetoh, Yuting Ma, Mikael J. Pittet, Oliver Kepp, Guido Kroemer
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-019-09415-3
Nature Communications 10/1 2019-07-09
2018 Alessandro Prestipino, Alica J. Emhardt, Konrad Aumann, David O’Sullivan, Sivahari P. Gorantla, Sandra Duquesne, Wolfgang Melchinger, Lukas Braun, Slavica Vuckovic, Melanie Boerries, Hauke Busch, Sebastian Halbach, Sandra Pennisi, Teresa Poggio, Petya Apostolova, Pia Veratti, Michael Hettich, Gabriele Niedermann, Mark Bartholomä, Khalid Shoumariyeh, Jonas S. Jutzi, Julius Wehrle, Christine Dierks, Heiko Becker, Annette Schmitt-Graeff, Marie Follo, Dietmar Pfeifer, Jan Rohr, Sebastian Fuchs, Stephan Ehl, Frederike A. Hartl, Susana Minguet, Cornelius Miething, Florian H. Heidel, Nicolaus Kröger, Ioanna Triviai, Tilman Brummer, Jürgen Finke, Anna L. Illert, Eliana Ruggiero, Chiara Bonini, Justus Duyster, Heike L. Pahl, Steven W. Lane, Geoffrey R. Hill, Bruce R. Blazar, Nikolas von Bubnoff, Erika L. Pearce, Robert Zeiser
Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
published pages: eaam7729, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aam7729
Science Translational Medicine 10/429 2019-07-09
2019 Nicole Prutsch, Elisabeth Gurnhofer, Tobias Suske, Huan Chang Liang, Michaela Schlederer, Simone Roos, Lawren C. Wu, Ingrid Simonitsch-Klupp, Andrea Alvarez-Hernandez, Christoph Kornauth, Dario A. Leone, Jasmin Svinka, Robert Eferl, Tanja Limberger, Astrid Aufinger, Nitesh Shirsath, Peter Wolf, Thomas Hielscher, Fritz Aberger, Johannes Schmoellerl, Dagmar Stoiber, Birgit Strobl, Ulrich Jäger, Philipp B. Staber, Florian Grebien, Richard Moriggl, Mathias Müller, Giorgio G. Inghirami, Takaomi Sanda, A. Thomas Look, Suzanne D. Turner, Lukas Kenner, Olaf Merkel
Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma
published pages: 696-709, ISSN: 0887-6924, DOI: 10.1038/s41375-018-0239-1
Leukemia 33/3 2019-07-09
2018 Luca Mologni, Mariantonia Costanza, Geeta Geeta Sharma, Michela Viltadi, Luca Massimino, Stefania Citterio, Stefania Purgante, Hima Raman, Alessandra Pirola, Massimo Zucchetti, Rocco Piazza, Carlo Gambacorti-Passerini
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells
published pages: 467-477, ISSN: 1476-5586, DOI: 10.1016/j.neo.2018.02.009
Neoplasia 20/5 2019-07-09
2017 Julie Frentzel, Domenico Sorrentino, Sylvie Giuriato
Targeting Autophagy in ALK-Associated Cancers
published pages: 161, ISSN: 2072-6694, DOI: 10.3390/cancers9120161
Cancers 9/12 2019-07-09

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ALKATRAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ALKATRAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

CALIPER (2019)

Creating Granular Materials Experts by Developing Experimental Calibrations for Computational Methods

Read More  

INFANS (2019)

INtegrating Functional Assessment measures for Neonatal Safeguard

Read More  

ACO (2019)

AstroChemical Origins

Read More